PDCD1 and non-small cell lung carcinoma: A pilot study including 20 patients with metastatic NSCLC with disease progression after first-line platinum-based chemotherapy were treated with sintilimab (checkpoint inhibitor, anti-PD-1 antibody) and autologous NK cells [236].